Navigation Links
Art Pappas Elected to NVCA Board of Directors
Date:5/15/2013

RESEARCH TRIANGLE PARK, N.C., May 15, 2013 /PRNewswire/ -- The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas , managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made official at the association's annual meeting – VentureScape 2013 – in San Francisco.

Mr. Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Ventures in 1994, and works with a team that has invested in numerous life science companies that have created novel innovative products addressing unmet medical needs. Prior to forming Pappas Ventures, he held senior level leadership positions at several multinational pharmaceutical companies, for which he led operations and was responsible for the development, licensing and launch of a number of global products.

The NVCA serves as the venture capital community's trade association, representing more than 400 members by advocating for policies that encourage innovation and reward long term investment.

"It is an honor and a pleasure to join the NVCA Board of Directors, especially during such a critical time for the venture capital industry," said Mr. Pappas. "I look forward to working with the organization and the board in developing policies that can further foster innovation and facilitate the creation of good jobs throughout the U.S. economy."

The NVCA also appointed Josh Green , general partner of Mohr Davidow Ventures to serve as the 2013-2014 Chairman of the Board of Directors, effective immediately. Mr. Pappas joins the board along with five other newly-elected directors; Scott Kupor , Andreessen Horowitz; Sue Siegel , GE healthymagination; John Backus , New Atlantic Ventures; Mark Leschly , Rho Capital Partners; and Jim Healy , Sofinnova Ventures.

About Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of more than 50 life sciences companies, including Arena Pharmaceuticals (Nasdaq: ARNA), Plexxikon (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), NuVasive (Nasdaq: NUVA), TESARO (Nasdaq: TSRO), and Chimerix (Nasdaq: CMRX). For more information about Pappas Ventures please visit www.pappasventures.com.

CONTACT:
Ford S. Worthy
fworthy@pappasventures.com
919-998-3330

 


'/>"/>
SOURCE Pappas Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SoundConnect Recently Selected by iCIMS, Inc.
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. ExakTime’s GeoTrakker Selected for 2013 Most Innovative Product Award Program
4. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
5. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
6. American Physical Society elected physicist Markus Aspelmeyer as a Fellow
7. Topricin Selected for Bruce Springsteen MusiCares’ Tribute Gala
8. Topricin Pain Relief and Healing Cream Selected by Healthy Holistic Living as one of the Top 100 Green Products of 2012
9. INRS: Professor Federico Rosei elected AAAS Fellow in recognition of his meritorious efforts to advance science
10. Cantrell Selected to Lead Kansas Bioscience Authority
11. Companies Selected to Present at AdvaMed 2012 Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)...  The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member. David Cox , ... North America ), will serve as his company,s ... pleased to have Ipsen and Dr. Cox join NPC ... "We welcome their insights in helping us identify and ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just ... software solution, LabKey Biologics . Built in collaboration with Just and designed ... Biologics provides drug research teams tools for biological entity registration, assay data integration, ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: ... to report compelling safety and clinical data from its phase ... 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for ... ... a complete safety profile at 6 months and showed no ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):